comparemela.com

Latest Breaking News On - Expanded immunohematology - Page 1 : comparemela.com

Quotient (QTNT) Reports Q4 Revenue of $9 8M, Loss of $26 87M, Provides Business Update

Quotient (QTNT) Reports Q4 Revenue of $9 8M, Loss of $26 87M, Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update

24.06.2022 - Financial Position Amended Secured Notes: Reduces the company’s cash obligations by approximately $93 million over the next 36 monthsAnnounces Public Equity Offering: Improving liquidity runwayFY 2022 Revenue of $38.5 Million$83.2 million in cash .

Quotient Limited Provides Update on CE Marking Progress of the MosaiQ™ Expanded Immunohematology Microarray

Quotient Limited Provides Update on CE Marking Progress of the MosaiQ™ Expanded Immunohematology Microarray
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

Quotient Limited Provides Fourth Quarter and Full Year

Quotient Limited Reports Third Quarter Fiscal 2021 Results and Business Update

Quotient Limited Reports Third Quarter Fiscal 2021 Results and Business Update Nachrichtenquelle: globenewswire  |  01.02.2021, 12:00  |  130  Expanded MosaiQ IH microarray EU launch planned for fourth quarter CY2021 Sales of Alba by Quotient reagents exceed guidance Strong cash position in place to carry us into commercialization JERSEY, Channel Islands, Feb. 01, 2021 (GLOBE NEWSWIRE) Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its third quarter fiscal 2021 results and other notable developments. Notable developments include the CE marking of the Company s MosaiQ semi-quantitative COVID-19 antibody test, which is an enhanced version of the Company s previously approved COVID antibody test.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.